Trevia Dosage/Direction for Use

The recommended dose of Sitagliptin (Trevia) is 100 mg once daily as monotherapy or as combination therapy with metformin HCl, a sulphonylurea, insulin (with or without metformin HCl), a PPARγ agonist (i.e., thiazolidinediones), metformin HCl plus a sulphonylurea, or metformin HCl plus a PPARγ agonist (i.e., thiazolidinediones).
When Sitagliptin (Trevia) is used in combination with a sulphonylurea or with insulin, a lower dose of sulphonylurea or insulin may be considered to reduce the risk of sulphonylurea or insulin-induced hypoglycemia.
Co-administration of a high-fat meal with Sitagliptin (Trevia) had no effect on the pharmacokinetics, Sitagliptin (Trevia) maybe administered with or without food.
If a dose of Sitagliptin (Trevia) is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day or as prescribed by the physician.
Special Populations: Renal Insufficiency: For patients with mild renal insufficiency (creatinine clearance [Cl_Cr] >50 mL/min, approximately corresponding to serum creatinine levels of <1.7 mg/dL in men and <1.5 mg/dL in women), no dosage adjustment for sitagliptin is required. For patients with moderate renal insufficiency (Cl_Cr >30 to <50 mL/min, approximately corresponding to serum creatinine levels of >1.7 to <3.0 mg/dL in men and >1.5 to <2.5 mg/dL in women), the dose of sitagliptin is 50 mg once daily. For patients with severe renal insufficiency (Cl_Cr <30 mL/min, approximately corresponding to serum creatinine levels of >3.0 mg/dL in men and >2.5 mg/dL in women) or with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis, the dose of sitagliptin is 25 mg once daily. Sitagliptin may be administered without regard to the timing of hemodialysis.
Elderly: No dose adjustment is required based on age.